These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 30753432)

  • 1. Heart failure with preserved ejection fraction, atrial fibrillation, and the role of senile amyloidosis.
    van den Berg MP; Mulder BA; Klaassen SHC; Maass AH; van Veldhuisen DJ; van der Meer P; Nienhuis HLA; Hazenberg BPC; Rienstra M
    Eur Heart J; 2019 Apr; 40(16):1287-1293. PubMed ID: 30753432
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction.
    González-López E; Gallego-Delgado M; Guzzo-Merello G; de Haro-Del Moral FJ; Cobo-Marcos M; Robles C; Bornstein B; Salas C; Lara-Pezzi E; Alonso-Pulpon L; Garcia-Pavia P
    Eur Heart J; 2015 Oct; 36(38):2585-94. PubMed ID: 26224076
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of clinical characteristics of patients with heart failure and preserved ejection fraction with atrial fibrillation versus sinus rhythm: Insights from the APOLLON registry.
    Özlek B; Özlek E; Tekinalp M; Kahraman S; Zencirkiran Agus H; Başaran Ö; Kaya BC; Rencüzoğulları İ; Mert KU; Çakır O; Ösken A; Bekar L; Çelik Y; Çil C; Doğan V; Çelik O; Mert GÖ; Memiç Sancar K; Sevinç S; Biteker M
    Turk Kardiyol Dern Ars; 2020 Apr; 48(3):234-245. PubMed ID: 32281959
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Features of atrial fibrillation in wild-type transthyretin cardiac amyloidosis: a systematic review and clinical experience.
    Mints YY; Doros G; Berk JL; Connors LH; Ruberg FL
    ESC Heart Fail; 2018 Oct; 5(5):772-779. PubMed ID: 29916559
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Atrial Fibrillation in Heart Failure With Preserved, Mid-Range, and Reduced Ejection Fraction.
    Sartipy U; Dahlström U; Fu M; Lund LH
    JACC Heart Fail; 2017 Aug; 5(8):565-574. PubMed ID: 28711451
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Applicability of H
    Jia XY; Liu LX; Wang DW; Ma XW; Liu YM
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2024 Apr; 46(2):154-160. PubMed ID: 38686710
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Atrial fibrillation in heart failure with preserved ejection fraction: Insights into mechanisms and therapeutics.
    Patel RB; Vaduganathan M; Shah SJ; Butler J
    Pharmacol Ther; 2017 Aug; 176():32-39. PubMed ID: 27773787
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Thromboembolisms in atrial fibrillation and heart failure patients with a preserved ejection fraction (HFpEF) compared to those with a reduced ejection fraction (HFrEF).
    Sobue Y; Watanabe E; Lip GYH; Koshikawa M; Ichikawa T; Kawai M; Harada M; Inamasu J; Ozaki Y
    Heart Vessels; 2018 Apr; 33(4):403-412. PubMed ID: 29067492
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical Phenotyping of Transthyretin Cardiac Amyloidosis with Bone-Seeking Radiotracers in Heart Failure with Preserved Ejection Fraction.
    Chen W; Ton VK; Dilsizian V
    Curr Cardiol Rep; 2018 Mar; 20(4):23. PubMed ID: 29520480
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Yield of bone scintigraphy screening for transthyretin-related cardiac amyloidosis in different conditions: Methodological issues and clinical implications.
    Tini G; Sessarego E; Benenati S; Vianello PF; Musumeci B; Autore C; Canepa M
    Eur J Clin Invest; 2021 Dec; 51(12):e13665. PubMed ID: 34390490
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Atrial Fibrillation in Heart Failure With Preserved Ejection Fraction: Association With Exercise Capacity, Left Ventricular Filling Pressures, Natriuretic Peptides, and Left Atrial Volume.
    Lam CS; Rienstra M; Tay WT; Liu LC; Hummel YM; van der Meer P; de Boer RA; Van Gelder IC; van Veldhuisen DJ; Voors AA; Hoendermis ES
    JACC Heart Fail; 2017 Feb; 5(2):92-98. PubMed ID: 28017355
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Atrial function in paroxysmal AF patients with and without heart failure with preserved ejection fraction: Data from the AF-RISK study.
    Artola Arita V; Santema BT; De With RR; Nguyen BO; Linz D; Schotten U; Van Gelder IC; Crijns HJ; Voors AA; Rienstra M
    Am Heart J; 2022 Feb; 244():36-41. PubMed ID: 34688651
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Screening for Unrecognized HFpEF in Atrial Fibrillation and for Unrecognized Atrial Fibrillation in HFpEF.
    Reddy YNV; Noseworthy P; Borlaug BA; Albert NM
    JACC Heart Fail; 2024 Jun; 12(6):990-998. PubMed ID: 38839160
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Right Heart Dysfunction in Heart Failure With Preserved Ejection Fraction: The Impact of Atrial Fibrillation.
    Gorter TM; van Melle JP; Rienstra M; Borlaug BA; Hummel YM; van Gelder IC; Hoendermis ES; Voors AA; van Veldhuisen DJ; Lam CSP
    J Card Fail; 2018 Mar; 24(3):177-185. PubMed ID: 29197548
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Most Predictive Red Flags for Suspecting Cardiac Amyloidosis in Patients with Heart Failure with Preserved Ejection Fraction.
    Yalvaç HE; Murat S; Ak Sivrikoz İ; Üsküdar Teke H; Çilingir O; Çolak E; Çavuşoğlu Y
    Turk Kardiyol Dern Ars; 2024 Jun; 52(4):227-236. PubMed ID: 38829635
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Atrial fibrillation and subtype of atrial fibrillation in cardiac amyloidosis: clinical and echocardiographic features, impact on mortality.
    Sanchis K; Cariou E; Colombat M; Ribes D; Huart A; Cintas P; Fournier P; Rollin A; Carrié D; Galinier M; Maury P; Duparc A; Lairez O;
    Amyloid; 2019 Sep; 26(3):128-138. PubMed ID: 31172799
    [No Abstract]   [Full Text] [Related]  

  • 17. Persistent atrial fibrillation in heart failure with preserved ejection fraction: Prognostic relevance and association with clinical, imaging and invasive haemodynamic parameters.
    Schönbauer R; Duca F; Kammerlander AA; Aschauer S; Binder C; Zotter-Tufaro C; Koschutnik M; Fiedler L; Roithinger FX; Loewe C; Hengstenberg C; Bonderman D; Mascherbauer J
    Eur J Clin Invest; 2020 Feb; 50(2):e13184. PubMed ID: 31732964
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Amplified P-wave duration predicts new-onset atrial fibrillation in patients with heart failure with preserved ejection fraction.
    Müller-Edenborn B; Minners J; Kocher S; Chen J; Zeh W; Lehrmann H; Allgeier J; Neumann FJ; Arentz T; Jadidi A
    Clin Res Cardiol; 2020 Aug; 109(8):978-987. PubMed ID: 31863175
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Determining patterns of vascular function and structure in wild-type transthyretin cardiac amyloidosis. A comparative study.
    Stamatelopoulos K; Delialis D; Georgiopoulos G; Tselegkidi MI; Theodorakakou F; Dialoupi I; Bambatsias D; Petropoulos I; Vergaro G; Ikonomidis I; Tzortzis S; Briasoulis A; Kanakakis J; Trougakos I; Dimopoulos MA; Kastritis E
    Int J Cardiol; 2022 Sep; 363():102-110. PubMed ID: 35716935
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Catheter ablation of atrial fibrillation in patients with heart failure and preserved ejection fraction.
    Black-Maier E; Ren X; Steinberg BA; Green CL; Barnett AS; Rosa NS; Al-Khatib SM; Atwater BD; Daubert JP; Frazier-Mills C; Grant AO; Hegland DD; Jackson KP; Jackson LR; Koontz JI; Lewis RK; Sun AY; Thomas KL; Bahnson TD; Piccini JP
    Heart Rhythm; 2018 May; 15(5):651-657. PubMed ID: 29222043
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.